What question did this study set out to answer?

To evaluate the efficacy and safety of long-term, low-dose glucocorticoid therapy in elderly patients with active rheumatoid arthritis using real-world clinical data.

June 24, 2025Modern Rheumatology JournalOpen Access

On the advisability of long-term use of low-dose glucocorticoids in elderly patients with rheumatoid arthritis

View Full Paper

Ask AI

Bookmark

Authors

АГА. В. Гордеев EME. V. Matyanova EZE. G. Zotkin

Discussion

Member takes

Overview

Retrospective cross-sectional study reveals elevated multimorbidity and delayed biologic therapy with long-term glucocorticoids in elderly rheumatoid arthritis, suggesting questionable utility.

Key Points

To evaluate the efficacy and safety of long-term, low-dose glucocorticoid therapy in elderly patients with active rheumatoid arthritis using real-world clinical data.
Conducted a retrospective cross-sectional analysis of hospitalized patients with active rheumatoid arthritis (N=967) who did not respond to conventional synthetic disease-modifying antirheumatic drugs.
Selected patients taking oral glucocorticoids for ≥6 months (n=658), comparing younger/middle-aged patients (18–59 years, n=385) with elderly patients (≥60 years, n=225).
Evaluated disease activity scores, structural progression, extra-articular manifestations, and coexisting conditions using the Cumulative Illness Rating Scale (CIRS).
Elderly patients received low-dose glucocorticoids for a median of 43 months (mean daily dose 6.2±3.3 mg), and treatment duration positively correlated with delayed initiation of biologic DMARDs.
Despite similar inflammatory disease activity scores, elderly patients had higher rates of joint surgeries (p<0.0001), total joint replacements (p=0.0009), and extra-articular manifestations (p=0.0006).
Elderly patients showed significantly increased rates of coronary artery disease (p<0.0001), osteoporosis (p<0.0001), chronic kidney disease (p<0.0001), diabetes (p=0.006), and a higher overall CIRS score (p<0.0001).

Cite This Study

Гордеев et al. (2025) studied this question.

synapsesocial.com/papers/6aaa0a05663efc0f708448c7 https://doi.org/10.14412/1996-7012-2025-3-80-86

View Full Paper

Ask AI

Bookmark

June 24, 2025Modern Rheumatology JournalOpen Access

On the advisability of long-term use of low-dose glucocorticoids in elderly patients with rheumatoid arthritis

View Full Paper

Ask AI

Bookmark

Authors

АГА. В. Гордеев EME. V. Matyanova EZE. G. Zotkin

Discussion

Member takes

Overview

Retrospective cross-sectional study reveals elevated multimorbidity and delayed biologic therapy with long-term glucocorticoids in elderly rheumatoid arthritis, suggesting questionable utility.

Key Points

To evaluate the efficacy and safety of long-term, low-dose glucocorticoid therapy in elderly patients with active rheumatoid arthritis using real-world clinical data.
Conducted a retrospective cross-sectional analysis of hospitalized patients with active rheumatoid arthritis (N=967) who did not respond to conventional synthetic disease-modifying antirheumatic drugs.
Selected patients taking oral glucocorticoids for ≥6 months (n=658), comparing younger/middle-aged patients (18–59 years, n=385) with elderly patients (≥60 years, n=225).
Evaluated disease activity scores, structural progression, extra-articular manifestations, and coexisting conditions using the Cumulative Illness Rating Scale (CIRS).
Elderly patients received low-dose glucocorticoids for a median of 43 months (mean daily dose 6.2±3.3 mg), and treatment duration positively correlated with delayed initiation of biologic DMARDs.
Despite similar inflammatory disease activity scores, elderly patients had higher rates of joint surgeries (p<0.0001), total joint replacements (p=0.0009), and extra-articular manifestations (p=0.0006).
Elderly patients showed significantly increased rates of coronary artery disease (p<0.0001), osteoporosis (p<0.0001), chronic kidney disease (p<0.0001), diabetes (p=0.006), and a higher overall CIRS score (p<0.0001).

Cite This Study

Гордеев et al. (2025) studied this question.

synapsesocial.com/papers/6aaa0a05663efc0f708448c7 https://doi.org/10.14412/1996-7012-2025-3-80-86

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark